
    
      This is an open-label, multi-center, randomized, Phase 2 study designed to compare the
      efficacy and safety of pegilodecakin in combination with pembrolizumab versus pembrolizumab
      alone in participants with stage IV / metastatic wild type non-small cell lung cancer and
      tumors with high expression of PD-L1 (> 50%).
    
  